---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-047805"
form_type: "8-K"
ticker: "RLMD"
cik: "0001553643"
company_name: "RELMADA THERAPEUTICS, INC."
filed_at: "2025-05-27T23:59:59+00:00"
generated_at: "2026-05-20T10:38:23.835552+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.15
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Relmada shareholders elect director, ratify auditor, approve 2M share increase to 2021 equity plan

## Summary
- Annual meeting held May 23, 2025; 53.6% quorum attained.
- John Glasspool elected Class I director (36-month term) with 7.14M for, 2.60M withheld.
- Ratification of CBIZ CPAs as auditor for FY2025 approved: 16.44M for, 0.86M against.
- Amendment to 2021 Plan approved: share pool increased by 2,000,000 to 9,900,000 total.
- Continuing Class II directors: Charles Casamento and Sergio Traversa; Class III: John Glasspool and Paul Kelly.

## SEC filing metadata
- accession: 0001213900-25-047805
- form_type: 8-K
- ticker: RLMD
- cik: 0001553643
- company_name: RELMADA THERAPEUTICS, INC.
- filed_at: 2025-05-27T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.15
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1553643/000121390025047805/0001213900-25-047805-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1553643/000121390025047805/ea0243544-8k_relmada.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-047805
- JSON: https://secwatch.observer/filing/0001213900-25-047805.json
- Plain text: https://secwatch.observer/filing/0001213900-25-047805.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.